Feedback (LSE:FDBK) Cash Conversion Cycle: -593.28 (As of Nov. 2025)


What is Feedback Cash Conversion Cycle?

Feedback LSE:FDBK Cash Conversion Cycle is -593.28 as of Nov. 2025. The stock has 4 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Feedback's Days Sales Outstanding for the six months ended in Nov. 2025 was 23.86.
Feedback's Days Inventory for the six months ended in Nov. 2025 was 0.
Feedback's Days Payable for the six months ended in Nov. 2025 was 617.14.
Therefore, Feedback's Cash Conversion Cycle (CCC) for the six months ended in Nov. 2025 was -593.28.


Feedback  (LSE:FDBK) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Feedback Cash Conversion Cycle Related Terms


Feedback Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Feedback's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feedback Cash Conversion Cycle Chart

Feedback Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,226.04 -585.91 -438.32 -536.25 -500.83

Feedback Semi-Annual Data
May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,360.77 -2,215.41 -1,767.23 -1,385.21 -593.28

LSE:FDBK vs VEEV, BTSG, TEM: Cash Conversion Cycle Comparison

For the Health Information Services subindustry, Feedback's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Feedback Cash Conversion Cycle vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Feedback's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Feedback's Cash Conversion Cycle falls into.



Feedback Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Feedback's Cash Conversion Cycle for the fiscal year that ended in May. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0.62+0-501.45
=-500.83

Feedback's Cash Conversion Cycle for the quarter that ended in Nov. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=23.86+0-617.14
=-593.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of -593.28 mean?
Feedback (LSE:FDBK) has a Cash Conversion Cycle of -593.28 as of Nov. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Feedback and its competitors.
Is Feedback's Cash Conversion Cycle too high?
Feedback's current Cash Conversion Cycle is -593.28.
How does Feedback's Cash Conversion Cycle compare to VEEV and BTSG?
Feedback's Cash Conversion Cycle of -593.28 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Feedback and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feedback's current Cash Conversion Cycle is -593.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feedback stock overvalued right now?
Based on GuruFocus' analysis, Feedback (LSE:FDBK) is currently considered Possible Value Trap. The stock's GF Value™ is £0.14, compared to a current price of £0.07 — trading 49.3% below its estimated fair value. The current Cash Conversion Cycle is -593.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Feedback (LSE:FDBK), the current Cash Conversion Cycle is -593.28 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Feedback Business Description

Other Exchanges GZM0:Germany
Address 3-7 Temple Avenue, 201 Temple Chambers, London, GBR, EC4Y 0DT
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making, and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. Its operating segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa, a regulated communication platform for sharing clinical results and supporting multidisciplinary teamwork, and CareLocker, a patient-facing platform that provides access and control over diagnostic and clinical data.